Anti-VEGF molecules for the management of diabetic macular edema

Research output: Contribution to journalArticlepeer-review


Diabetic macular edema (DME) represents the most common cause of vision loss in patients affected by diabetes mellitus. Although the pathophysiology of DME is not wholly understood, vascular endothelial growth factor (VEGF) has been identified as a key contributor to the development of DME. In addition, latest information suggests that acute and chronic inflammatory changes occur, contributing to the DME pathogenesis. The current therapeutic approach for DME is mainly based on the administration of anti-VEGF molecules. In particular, VEGF-inhibitors that have been studied for diabetic retinopathy include pegaptanib, ranibizumab, bevacizumab, and aflibercept. The present review analyzes the main characteristics of each molecule, describing the most important results of clinical trails.

Original languageEnglish
Pages (from-to)4731-4737
Number of pages7
JournalCurrent Pharmaceutical Design
Issue number32
Publication statusPublished - Oct 1 2015


  • Anti-vascular endothelial growth factor
  • Diabetic macular edema
  • Diabetic retinopathy

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology


Dive into the research topics of 'Anti-VEGF molecules for the management of diabetic macular edema'. Together they form a unique fingerprint.

Cite this